Volume : 11, Issue : 09, September – 2024

Title:

STABILITY INDICATING METHOD DEVELOPMENT AND VALIDATION OF IMATINIB MESYLATE BY RP-HPLC

Authors :

J.Jhansi, Dr. Varun, M.Kavya, B.Haritha, S.K. Godasu

Abstract :

A simple,fast and precise reverse phase high performance liquid chromatographic method (Rp-HPLC) good sensitivity was determined for the development and validation of Imatinib Mesylate. A Elico,corp.Japan UV-Visible spectrophotometer was used. The chromatographic separation was achieved on a waters C18 column,5um,150X4.6mm as stationary phase with mobile phase Methanol, Acetonitrile, Dichloromathane, Water, 0.1N NaOH, 0.1N HCl. An isocratic elution mode at 1.0mi/min flow rate and maintaining column temperature at ambient. The detection was monitored at 200-250nm for Imatinib Mesylate. The linearity was found to be in the range of 0-35ug/ml. The calibration factor is 0.9963. Imatinib Mesylate was subjected to p acidic, basic, oxidative, thermal and photolytic degradation. The drug was found to be stable in all the conditions. The developed method was simple, accurate, precise, specific, sensitive & reproducible. Stress testing should be given importance for quantification of degraded products of drugs helps us to maintain the quality, safety & efficacy of drugs in formulations.
Keywords: Imatinib mesylate, linearity, calibration factor, degradation.

Cite This Article:

Please cite this article in press J. Jhansi et al., Stability Indicating Method Development And Validation Of Imatinib Mesylate By RP-HPLC., Indo Am. J. P. Sci, 2024; 11 (09).

Number of Downloads : 10

References:

1. Iqbal N, Iqbal N: Imatinib: a breakthrough of targeted therapy in cancer. Chemother Res Pract. 2014;2014:357027. doi: 10.1155/2014/357027. Epub 2014 May 19.
2. Greuber EK, Smith-Pearson P, Wang J, Pendergast AM: Role of ABL family kinases in cancer: from leukaemia to solid tumours. Nat Rev Cancer. 2013 Aug;13(8):559-71. doi: 10.1038/nrc3563. Epub 2013 Jul 11.
3. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996 May;2(5):561-6. doi: 10.1038/nm0596-561.
4. Patil SJ, Doijad RC and Dhumal PP: Development of UV Spectrophotometric Method for determination of Imatinib Mesylate in Bulk & Formulation. Asian Journal of Pharmaceutical and Clinical Research 2013; 6(3):54-57.
5. Bende G, Kollipare S, Sekar V and Saha R: UV Spectrophotometric determination of Imatinib mesylate and its application in solubility studies. Pharmazine 2008; 63(9):641-645.
6. Kumar RJ and Kumar SN: Validated Spectrophotometric estimation of Imatinib Mesylate in pure & tablet dosage form. International Journal of Pharmacy & Technology 2010; 2(3):490-495.
7. Vadera N, Subramanian G and Musmade P: Stability indicating HPTLC determination of Imatinib Mesylate in Bulk drug & Pharmaceutical dosage. Journal of pharmaceutical and biomedical analysis 2007; 43(2):722- 726.
8. Velpandian T, Mathur R, Agarwal NK, Arora B, Kumar L and Gupta SK: Development & Validation of simple liquid chromatographic method with ultraviolet detection for the determination of Imatinib in Biological sample. Journal of Chromatogrphy. B Analytical technologies in the biomedical and life Sciences 2004; 804(2):431-434.
9. Vivekanand VV, Sreenivas RD, Vaidyanathan G, Sekhar NM, Avijit KS and Ramachandra PP: A Validated LC method for Imatinib Mesylate. Journal of pharmaceutical and biomedical analysis 2003; 33(5):879-889.
10. Aleti P, Venisetty RK and Kamarapu SK: Development of RP-HPLC method for analysis of Imatinib Mesylate using PDA Detector & its application in the evaluation of marketed preparation. International Journal of Pharmacy and Biological Sciences 2011; 1(2):14-18.
11. Negi LM, Jaggi M and Talegaonkar S: Development of High Sensitivity RP-HPLC method & Stress Testing of Imatinib Mesylate. Journal of Advanced Pharmacy Education & Research 2013; 3(3): 238-243.
12. Sandhya P, Vishnu PP and Anjali ND: Method development and validation of Imatinib Mesylate in Pharmaceutical dosage form by RP-HPLC. World Journal of Pharmacy and Pharmaceutical Sciences 2013; 3(1):682- 688.
13. Maria AR, Maria AM, Maria TP and Adriana IS: Validation of an HPLC Method for the Determination of Imatinib Mesylate in Pharmaceutical dosage. Journal of Liquid Chromatography & Related Technologies 2013; 28(20):3283-3292